Current treatment options in patients with mastocytosis: status in 2015 and future perspectives - PubMed (original) (raw)
Review
doi: 10.1111/ejh.12544. Epub 2015 Mar 26.
Affiliations
- PMID: 25753531
- DOI: 10.1111/ejh.12544
Review
Current treatment options in patients with mastocytosis: status in 2015 and future perspectives
Michel Arock et al. Eur J Haematol. 2015 Jun.
Abstract
Mastocytosis is a term referring to a heterogeneous group of disorders characterized by abnormal mast cell (MC) accumulation in the skin and/or internal organs. In children, the disease involves mostly the skin (cutaneous mastocytosis; CM), whereas in adults, the disease is usually systemic (systemic mastocytosis; SM). Advanced SM variants with end-organ damage and reduced life expectancy have also been described, but are rare. Clinical signs and symptoms in SM result from excessive mediator release by MCs and, in aggressive forms, from organ failure related to MC infiltration. As a consequence, treatment of indolent SM aims primarily at the control of symptoms caused by MC mediator release. By contrast, in advanced SM, such as aggressive SM, MC leukemia, and MC sarcoma, intensive (chemo)therapy with or without allogeneic stem cell transplantation has to be considered. In addition, activating mutations in KIT (mostly KIT D816V in adults) are found in most patients with SM, so that targeted therapies aimed at blocking mutant KIT variants or/and downstream signaling pathways are currently being developed. Other targets, such as specific surface antigens expressed on neoplastic MCs, might be considered for the development of future therapies in advanced SM.
Keywords: KIT mutations; allogeneic stem cell transplantation; antihistamines; cytoreduction; mastocytosis; surface antigens; targeted therapy; tyrosine kinase inhibitors.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
- Mastocytosis: state of the art.
Horny HP, Sotlar K, Valent P. Horny HP, et al. Pathobiology. 2007;74(2):121-32. doi: 10.1159/000101711. Pathobiology. 2007. PMID: 17587883 Review. - Pharmacological treatment options for mast cell activation disease.
Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL, Panse J, Butterfield J, Afrin LB. Molderings GJ, et al. Naunyn Schmiedebergs Arch Pharmacol. 2016 Jul;389(7):671-94. doi: 10.1007/s00210-016-1247-1. Epub 2016 Apr 30. Naunyn Schmiedebergs Arch Pharmacol. 2016. PMID: 27132234 Free PMC article. Review. - Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
Valent P. Valent P. Hematology Am Soc Hematol Educ Program. 2015;2015:98-105. doi: 10.1182/asheducation-2015.1.98. Hematology Am Soc Hematol Educ Program. 2015. PMID: 26637707 Review. - [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K. Sotlar K. Verh Dtsch Ges Pathol. 2007;91:169-76. Verh Dtsch Ges Pathol. 2007. PMID: 18314612 German. - [Mastocytosis, classification, biological diagnosis and therapy].
Arock M. Arock M. Ann Biol Clin (Paris). 2004 Nov-Dec;62(6):657-69. Ann Biol Clin (Paris). 2004. PMID: 15563424 Review. French.
Cited by
- Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment.
Zmorzynski S, Kimicka-Szajwaj A, Szajwaj A, Czerwik-Marcinkowska J, Wojcierowski J. Zmorzynski S, et al. Genes (Basel). 2024 Jan 22;15(1):137. doi: 10.3390/genes15010137. Genes (Basel). 2024. PMID: 38275618 Free PMC article. Review. - Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V+ systemic mastocytosis: a preclinical study.
Degenfeld-Schonburg L, Gamperl S, Stefanzl G, Schruef AK, Sadovnik I, Bauer K, Smiljkovic D, Eisenwort G, Peter B, Greiner G, Hadzijusufovic E, Schwaab J, Sperr WR, Hoermann G, Kopanja S, Szépfalusi Z, Hoetzenecker K, Jaksch P, Reiter A, Arock M, Valent P. Degenfeld-Schonburg L, et al. Am J Cancer Res. 2023 Feb 15;13(2):355-378. eCollection 2023. Am J Cancer Res. 2023. PMID: 36895976 Free PMC article. - Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate.
Brown GK, Finlay JR, Straw RC, Ziea JY, Leung B, O'Connell K, Thomson MJ, Campbell JE, Jones PD, Reddell P. Brown GK, et al. Front Vet Sci. 2022 Oct 26;9:1003165. doi: 10.3389/fvets.2022.1003165. eCollection 2022. Front Vet Sci. 2022. PMID: 36387404 Free PMC article. - Activating Mutation in the Receptor Tyrosine Kinase FLT3 with Clinicopathological Relevance in Canine Mast Cell Tumors.
Manachai N, Rattanapinyopituk K, Fonghem P, Phoomvuthisarn P, Nakahata S, Morishita K, Rungsipipat A. Manachai N, et al. Vet Med Int. 2022 Aug 28;2022:9509900. doi: 10.1155/2022/9509900. eCollection 2022. Vet Med Int. 2022. PMID: 36072760 Free PMC article. - Rare gastrointestinal presentation of systemic mastocytosis, a case report.
Javadi AE, Nazar E, Momeni N. Javadi AE, et al. Ann Med Surg (Lond). 2022 Jul 13;80:104196. doi: 10.1016/j.amsu.2022.104196. eCollection 2022 Aug. Ann Med Surg (Lond). 2022. PMID: 36045813 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials